| Zeit | Aktuelle Nachrichten
| | Leser | Medien |
|---|
| 05:31 | Cipher Pharmaceuticals announces FDA approval of CIP-ISOTRETINOIN | | 42 | PR Newswire |
| Product to be launched as Absorica™
Toronto Stock Exchange Symbol: DND
MISSISSAUGA, ON, May 27, 2012 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX:
DND; OTC: CPHMF.PK) announced today that...
Mehr lesen zu:
Cipher Pharmaceuticals announces FDA approval of CIP-ISOTRETINOIN | |
| 04:39 | Cyclopharm - AGM Presentation Audio Broadcast | | - | wotnews |
| 04:27 | CELLMID LIMITED - Results of Meeting | | - | wotnews |
| 01:11 | Eisai erhält von europäischer arzneimittelagentur positive stellungnahme zu neuem antiepileptikum Fycompa® (perampanel) | | 98 | news aktuell |
| Hatfield, Großbritannien (ots/PRNewswire) - CHMP veröffentlicht ausserdem positive Stellungnahme zum Einsatzvon Eisais Zonegran(R) (Zonisamid) in der Monotherapie fokaler Anfälle Eisai gab heute...
Mehr lesen zu:
Eisai erhält von europäischer arzneimittelagentur positive stellungnahme zu neuem antiepileptikum Fycompa® (perampanel) | |
| 01:07 | Eisai Gains Positive CHMP Opinion for Fycompa® (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy | | 61 | PR Newswire |
| HATFIELD, England, May 28, 2012 /PRNewswire/ --
CHMP also issues positive opinion for monotherapy use of Eisai's Zonegran®(zonisamide)
Eisai announced today that the European Medicines Agency's...
Mehr lesen zu:
Eisai Gains Positive CHMP Opinion for Fycompa® (perampanel) First in a New Class of Treatment for Partial Onset Epilepsy | |
| 01:03 | Eisai Receives Positive CHMP Opinion for Zonegran® (Zonisamide) Monotherapy Treatment for Epilepsy | | 62 | PR Newswire |
| HATFIELD, England, May 28, 2012 /PRNewswire/ --
Eisai also receives CHMP recommendation for EU approval of Fycompa®(perampanel)
Eisai announced today that the European Medicines Agency's Committee...
Mehr lesen zu:
Eisai Receives Positive CHMP Opinion for Zonegran® (Zonisamide) Monotherapy Treatment for Epilepsy | |
| 01:02 | Eisai Gains Positive CHMP Opinion for Fycompa® (perampanel) First in a new Class of Treatment for Focal Epilepsy | | 65 | PR Newswire |
| HATFIELD, England, May 28, 2012 /PRNewswire/ --
CHMP also issues positive opinion for monotherapy use of Eisai's Zonegran®(zonisamide)
Eisai announced today that the European Medicines Agency's...
Mehr lesen zu:
Eisai Gains Positive CHMP Opinion for Fycompa® (perampanel) First in a new Class of Treatment for Focal Epilepsy | |
| 00:01 | XFRA DIVIDEND INFORMATION - 29.05.2012 - 2 | | 101 | Xetra Newsboard |
| FOLGENDE WERTPAPIERE WERDEN AM 28.05.2012 CUM DIVIDENDE UND AM 29.05.2012
EX DIVIDENDE GEHANDELT.
THE PRE-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 28.05.2012. THE
EX-DIVIDEND DAY WILL BE 29.05.2012.
...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 29.05.2012 - 2 | |
| 27.05.
| Novartis-Präsident Vasella kritisiert die Einwanderungspolitik | | 1 | Tages-Anzeiger |
| 27.05.
| Shares of PDL BioPharma Rank the Highest in Terms of Earnings Yield in the Biotechnology Industry | | 1 | SmarTrend |
| 27.05.
| Shares of Cambrex Rank the Highest in Terms of Earnings Yield in the Life Sciences Tools & Services Industry | | - | SmarTrend |
| 27.05.
| Elan top brass will get mega new bonus scheme | | - | Irish Independent |
| 26.05.
| Is Teva Pharmaceuticals An 'Investment Classic'? | | 10 | Seeking Alpha |
| 26.05.
| Sanofi, Regeneron Publish Results For Lipid-Lowering PCSK9 Antibody In Lancet | | 240 | AFX News |
| PARIS (dpa-AFX) - Sanofi (SNY) and Regeneron Pharmaceuticals Inc. (REGN)
announced additional positive results from a Phase 2 trial of SAR236553/REGN727
(Study 1003, NTC01266876) in patients...
Mehr lesen zu:
Sanofi, Regeneron Publish Results For Lipid-Lowering PCSK9 Antibody In Lancet | |
| 26.05.
| Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet | | 166 | PR Newswire |
| PARIS and TARRYTOWN, New York, May 26, 2012 /PRNewswire/ --
Global Phase 3 program of SAR236553/REGN727 to be initiated in June across multiple patient populations
Sanofi (EURONEXT: SAN and NYSE:...
Mehr lesen zu:
Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet | |
| 26.05.
| Stryker is Among the Companies in the Health Care Equipment Industry With the Highest Level of Cash | | - | SmarTrend |
| 26.05.
| Dubai Health Authority and Sanofi continue momentum to fight diabetes | | 1 | AME Info |
| 26.05.
| Rosen Law Firm Files Class Action Against Tibet Pharmaceuticals, Inc. – TBET | | 138 | Business Wire |
| The Rosen Law Firm, P.A. today announced that it has filed a class
action lawsuit on behalf of investors who purchased the securities of
Tibet Pharmaceuticals, Inc. ("Tibet...
Mehr lesen zu:
Rosen Law Firm Files Class Action Against Tibet Pharmaceuticals, Inc. – TBET | |
| 25.05.
| Sucampo Pharmaceuticals Up 90.1% Since SmarTrend Uptrend Call | | - | SmarTrend |
| 25.05.
| Pharmascience acquires securities of Bellus Health Inc. | | - | CNX Marketlink |
